Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ ... Breakthroughs in medical technology, ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.

Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance. Gilead ...

Prior to joining Gilead Canada, Paul most recently led Jazz Pharmaceuticals, where he built their Canadian organization over ...